Database

Startups

Main Industry
Biotechnology
Main Product/Service
Their lead asset, ASD141, is a first‑in‑class monoclonal antibody that blocks the innate immune checkpoint TLT‑1 to reshape the tumor microenvironment and enhance anti‑tumor immunity.
They are also developing ASD001, an antibody aimed at rebalancing over
Founded Year
2019
Unified Business No.
85070076
Status
Active
Number of Employees
0
Total Paid-in Capital
0 (NT$)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you. Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
About the Company
Ascendo Biotechnology, founded in 2019, is a clinical‑stage biotech company developing novel immunotherapies by targeting innate immune pathways to treat cancer and autoimmune diseases.



More ↓

Similar Companies

Taiwan Bio-Manufacturing Corporation

TBMC will leverage existing resources to integrate intelligent and smart platform to establish various biopharmaceuticals manufacturing facility.

U-NEURON BIOMEDICAL INC.

State-level Storage Equipment and Technology
U-NEURON BIOMEDICAL is devoted to the development of stem cell isolation, storage and clinical applications. It owns the Patent on the Technology of Isolation and Culture of Amniotic Fluid Stem Cell, and has si

ImmunAdd Inc.

ImmunAdd develops innovative and practical solutions for human health. We aim to harness the immune system to create next-generation immunotherapeutics for the treatment of infectious diseases and cancer. Our next-generation adjuvants provide better immun

ANYA BIOPHARM INC.

ORAL PEPTIDE
Summary of development timelines-product
MIRA/JE® Design
Lead Optimization
Preclinical Studies
Phase I
Phase II
Phase III
ANY002 Oral GLP1 product A: Prototype with human PK results available
ANY004 Oral GLP1 product B: Prototype in animal st